Legal / IP

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
HKG: 6628Patents

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Transcenta Holding Limited (HKG: 6628) announced that it has been granted an invention patent by the China National Intellectual Property Administration (CNIPA) covering the anti-CLDN18.2 antibodies independently developed by the…

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
HKG: 2359SHA: 603259

US Senate Committee Backs Bill to Restrict Chinese Biotechnology Firms’ Access to American Genetic Data

AlzeCure Pharma

AlzeCure Pharma’s Alzheimer’s Drug Candidate ACD856 Receives Global Patent Awards

NovartisNYSE: NVS

Sandoz Agrees to $265 Million Settlement in U.S. Generic Drug Antitrust Case

GSKNYSE: GSK

GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book

Show More